For example, the activity and safety of the VEGF neutralizing antibody bevacizumab in combination with pembrolizumab or atezolizumab is tested in clinical trial for patients with untreated BrM (NCT02681549; melanoma and NSCLC and NCT03175432 BEAT-MBM; melanoma). This evidence concerns the gene VEGFA and melanoma.